Antibiotic combination for bloodstream urinary infections
Part of Infections clinical trials.
This trial tests a combination of two antibiotics (cefepime and enmetazobactam) to treat complicated urinary tract infections that have spread to the blood. It aims to see if this new combination works better than other antibiotics and is safe for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a urinary tract infection that has spread to your blood, caused by certain bacteria.
- You must be willing to sign a consent form to participate.
- You must not have other types of bacteria (like Gram-positive or fungi) in your blood at the same time.
- You must not be allergic to certain antibiotics like cefepime or similar drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether using two or more antibiotics together works better than one alone for a specific type of blood infection caused by Enterococcus faecalis bacteria. The goal is to find the safest and most effective way to treat this infection and improve outcomes for patients.
This trial looks at how well two antibiotics, ceftazidime-avibactam and fosfomycin, work together to treat infections caused by highly resistant bacteria called CRE. It may help find the best way to use these medicines.
This study tests a new IV antibiotic combination (cefepime-enmetazobactam) for children with complicated urinary tract infections or kidney infections. The goal is to see how well it works and if it is safe.
This trial tests whether the antibiotic cefotetan works as well as current standard treatments for E. coli bloodstream infections that start in the urinary tract. If you qualify, you may receive either cefotetan or the usual antibiotic therapy.
This trial tests a new antibiotic combo (ertapenem-zidebactam) against an existing one (ceftazidime-avibactam) for serious urinary tract or kidney infections in hospitalized patients. It aims to see if the new drug is as effective and safe.
This trial tests whether piperacillin-tazobactam works as well as meropenem to treat bloodstream infections caused by certain E. coli or Klebsiella germs that resist common cephalosporin antibiotics. It may help you avoid a “bigger” antibiotic if the study drug is equally effective.
Hear when a new Antibiotic Resistance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.